Physician profile
Ali Mahdavi
NPI 1578628350
$4,447.50
in general payments reported to CMS, 2019-2025
10 companies · $397 in 2025
The $397 reported for 2025 was more than what a typical Gynecologic Oncology provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $250 · 2020: $23.47 · 2021: $125 · 2022: $1,539 · 2023: $614 · 2024: $1,499 · 2025: $397.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,569 · Food and Beverage: $941.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,569.09 |
| Food and Beverage | $941.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $2,819.13 | 2022-2024 | Enseal |
| Intuitive Surgical, INC. | $714.36 | 2020-2025 | Da Vinci Surgical System |
| Glaxosmithkline, LLC. | $342.26 | 2021-2025 | Jemperli |
| Ethicon US, LLC | $195.29 | 2023-2025 | Stratafix, Enseal, Vistaseal |
| Astrazeneca Pharmaceuticals LP | $125.00 | 2019 | |
| Tesaro, INC. | $124.91 | 2019 | |
| Eisai INC. | $60.15 | 2022 | |
| Abbvie INC. | $34.44 | 2025 | |
| Merck Sharp & Dohme LLC | $19.08 | 2022 | |
| Pfizer INC. | $12.88 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Mahdavi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.